Home Care Use of Intravenous and Subcutaneous Immunoglobulin for Primary Immunodeficiency in the United States

[1] Darabi K(2006)Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature Transfusion 46 741-53

[2] Abdel-Wahab O(2006)Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology J Allergy Clin Immunol 117 S525-53

[3] Dzik WH(2010)The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline Transfus Med Rev 24 S28-50

[4] Orange JS(2010)Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years J Allergy Clin Immunol 125 1354-60.e4

[5] Hossny EM(2011)Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD J Clin Immunol 31 924-6

[6] Weiler CR(2000)The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy J Clin Immunol 20 94-100

[7] Ballow M(2006)Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study J Clin Immunol 26 177-85

[8] Berger M(2011)Immunoglobulin treatment in primary antibody deficiency Int J Antimicrob Agents 37 396-404

[9] Bonilla FA(2008)Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection J Allergy Clin Immunol 122 210-2

[10] Shehata N(1994)Immune globulin use at a multihospital medical center Am J Hosp Pharm 51 801-5

[1] Darabi K(2006)Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature Transfusion 46 741-53

[2] Abdel-Wahab O(2006)Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology J Allergy Clin Immunol 117 S525-53

[3] Dzik WH(2010)The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline Transfus Med Rev 24 S28-50

[4] Orange JS(2010)Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years J Allergy Clin Immunol 125 1354-60.e4

[5] Hossny EM(2011)Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD J Clin Immunol 31 924-6

[6] Weiler CR(2000)The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy J Clin Immunol 20 94-100

[7] Ballow M(2006)Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study J Clin Immunol 26 177-85

[8] Berger M(2011)Immunoglobulin treatment in primary antibody deficiency Int J Antimicrob Agents 37 396-404

[9] Bonilla FA(2008)Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection J Allergy Clin Immunol 122 210-2

[10] Shehata N(1994)Immune globulin use at a multihospital medical center Am J Hosp Pharm 51 801-5